Eosinophil depletion by anti–Siglec-F reverses arterial thrombosis and reduces EETs and NETs in Lnk−/− mice. (A) Eosinophil, neutrophil, and platelet counts in WT and Lnk−/− mice treated with isotype control antibody or anti–Siglec-F antibody (20 μg per mice, 24 hours, IV injection). (B) FeCl3-induced carotid artery occlusion in WT and Lnk−/− mice treated with isotype control antibody or anti–Siglec-F antibody. (C) Representative images of Fibrinogen (red) staining and EETs staining in carotid artery thrombi of WT and Lnk−/− treated with isotype control antibody or anti–Siglec-F antibody. EETs were quantified using MBP (green) with H3Cit (red); n = 4 per group. (D) Representative images and quantifications of NETs using myeloperoxidase (MPO) (green) with H3Cit (red) in thrombi of WT and Lnk−/− treated with isotype control antibody or anti–Siglec-F antibody (n = 4 per group). (E) Quantification of eosinophil number (MBP+CD11b+) and neutrophil number (MPO+DAPI+) per thrombi. Scale bar, 100 μm. DAPI, 4′,6-diamidino-2-phenylindole.
